<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672932</url>
  </required_header>
  <id_info>
    <org_study_id>CCRC5004</org_study_id>
    <secondary_id>R01MH062701</secondary_id>
    <nct_id>NCT00672932</nct_id>
  </id_info>
  <brief_title>Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients</brief_title>
  <official_title>Pilot Study of Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study focuses on the persistence of central nervous system (CNS) immune activation
      that has been observed in the presence of 'effective' combination antiretroviral therapy
      (cART). Attention to this issue is based on the fear that chronic CNS immunoactivation can
      cause indolent brain injury that will eventually compromise brain function as patients
      survive for years on treatment. A leading hypothesis explaining this continued
      immunoactivation is that viral replication continues within the brain at a level too low for
      detection in cerebrospinal fluid (CSF), yet sufficient to stimulate local immunoactivation.
      Based on this hypothesis, we propose to use augmented treatment with raltegravir to test
      whether additional suppression of this hypothesized CNS HIV-1 replication will reduce
      continued CNS immunoactivation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CSF Concentrations of Neopterin After 12 Weeks</measure>
    <time_frame>three months (Rollover subjects were assessed for a second baseline after the initial 12 week period)</time_frame>
    <description>CSF markers of immunoÂ¬activation and inflammation after 12 weeks compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD8+ T Cell Co-expression of CD38 and HLA-DR</measure>
    <time_frame>three months (Rollover subjects were assessed for a second baseline after the initial 12 week period)</time_frame>
    <description>Blood CD8+ T cell activation as indicated by percentage of cells in fresh specimens coexpressing surface CD38 and human leukocyte antigen (HLA)-DR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>raltegravir group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No augmented treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>400 mg two times daily for three months</description>
    <arm_group_label>raltegravir group</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capacity to provide informed consent.

          -  Documented HIV-1 infection.

          -  History of continuous cART treatment (with at least three drugs) for at least 2 years.

          -  Documentation of 'undetectable' plasma HIV-1 RNA for at least 1 year.

          -  HIV-1 RNA &lt;50 copies/mL in plasma and CSF at screening visit.

        Exclusion Criteria:

          -  Contraindication to LP (suspicion of CNS mass lesion, bleeding diathesis, etc.).

          -  Prior experience with raltegravir or contraindication to raltegravir treatment,
             including medication interactions that might compromise ongoing antiretroviral therapy
             or treatment of other conditions.

          -  Active opportunistic infections or neurological diseases.

          -  Other conditions or treatments likely to interfere with treatment or evaluation.

          -  Hemoglobin &lt; 10 Gm/dL.

          -  Pregnant or anticipating pregnancy during study.

          -  Active substance abuse.

          -  Subjects taking rifampin, phenytoin, Phenobarbital or other drugs that accelerate
             raltegravir metabolism and might decrease its tissue concentrations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucsf Ccrc, Sfgh</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, Fuchs D, Palmer S, Price RW. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis. 2011 Dec 15;204(12):1936-45. doi: 10.1093/infdis/jir667. Epub 2011 Oct 21.</citation>
    <PMID>22021620</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>June 18, 2012</results_first_submitted>
  <results_first_submitted_qc>May 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 5, 2013</results_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>raltegravir</keyword>
  <keyword>central nervous system (CNS)</keyword>
  <keyword>HIV-1</keyword>
  <keyword>AIDS</keyword>
  <keyword>cerebrospinal fluid (CSF)</keyword>
  <keyword>immunoactivation</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>suppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir Group</title>
          <description>The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.</description>
        </group>
        <group group_id="P2">
          <title>No Augmented Treatment Then Optional Rollover</title>
          <description>Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen. After 12 weeks, subjects in this group have the option to rollover into the raltegravir group for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Initial 12-week Assignment</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Provided Analyzable Blood and CSF Sample</title>
              <participants_list>
                <participants group_id="P1" count="8">one subject was censored when pharmacological study showed no drug in plasma or CSF</participants>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rolled Over to Raltegravir</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6">6 subjects randomized to no drug later rolled over to receive raltegravir</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir Group</title>
          <description>The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.</description>
        </group>
        <group group_id="B2">
          <title>No Augmented Treatment</title>
          <description>Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="6.4"/>
                    <measurement group_id="B2" value="54.3" spread="5.3"/>
                    <measurement group_id="B3" value="53.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD8+ T Cell Co-expression of CD38 and HLA-DR</title>
        <description>Blood CD8+ T cell activation as indicated by percentage of cells in fresh specimens coexpressing surface CD38 and human leukocyte antigen (HLA)-DR.</description>
        <time_frame>three months (Rollover subjects were assessed for a second baseline after the initial 12 week period)</time_frame>
        <population>One subject in the raltegravir group was censored when a pharmacological study showed no drug in either plasma (n=9) or CSF. Six subjects randomized to no drug later rolled over to receive raltegravir. Primary analysis treated the rollover subjects as independent and compared 14 intensified to 9 nonintensified subject experiences.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Group</title>
            <description>The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.</description>
          </group>
          <group group_id="O2">
            <title>No Augmented Treatment</title>
            <description>Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD8+ T Cell Co-expression of CD38 and HLA-DR</title>
          <description>Blood CD8+ T cell activation as indicated by percentage of cells in fresh specimens coexpressing surface CD38 and human leukocyte antigen (HLA)-DR.</description>
          <population>One subject in the raltegravir group was censored when a pharmacological study showed no drug in either plasma (n=9) or CSF. Six subjects randomized to no drug later rolled over to receive raltegravir. Primary analysis treated the rollover subjects as independent and compared 14 intensified to 9 nonintensified subject experiences.</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="1.03"/>
                    <measurement group_id="O2" value="0.66" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in CSF Concentrations of Neopterin After 12 Weeks</title>
        <description>CSF markers of immunoÂ¬activation and inflammation after 12 weeks compared to baseline.</description>
        <time_frame>three months (Rollover subjects were assessed for a second baseline after the initial 12 week period)</time_frame>
        <population>One subject in the raltegravir group was censored when a pharmacological study showed no drug in either plasma (n=9) or CSF. Six subjects randomized to no drug later rolled over to receive raltegravir. Primary analysis treated the rollover subjects as independent and compared 14 intensified to 9 nonintensified subject experiences.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Group</title>
            <description>The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.</description>
          </group>
          <group group_id="O2">
            <title>No Augmented Treatment</title>
            <description>Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CSF Concentrations of Neopterin After 12 Weeks</title>
          <description>CSF markers of immunoÂ¬activation and inflammation after 12 weeks compared to baseline.</description>
          <population>One subject in the raltegravir group was censored when a pharmacological study showed no drug in either plasma (n=9) or CSF. Six subjects randomized to no drug later rolled over to receive raltegravir. Primary analysis treated the rollover subjects as independent and compared 14 intensified to 9 nonintensified subject experiences.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>6 subjects who rolled over to treatment after 12 weeks of no treatment were followed for an additional 12 weeks. 1 subject in the Raltegravir group was not included in other analyses because a pharmacological study showed no drug in either plasma or CSF.</desc>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir Group</title>
          <description>The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.</description>
        </group>
        <group group_id="E2">
          <title>No Augmented Treatment</title>
          <description>Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The underlying hypothesis might not have actually been addressed because of the particular makeup of the subject group with minimal CNS infection and immunoactivation that left little room to discern a therapeutic effect.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Richard W. Price, M.D.</name_or_title>
      <organization>UCSF</organization>
      <phone>415-206-4487</phone>
      <email>rwprice@sfgh.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

